宫腔镜检查在 I 期子宫内膜癌诊断中的肿瘤安全性：系统评价和荟萃分析方案。
Oncological safety of hysteroscopy in the diagnosis of stage I endometrial cancer: protocol for a systematic review and meta-analysis.
机构信息
Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China.
Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China.
出版信息
BMJ Open. 2020 Dec 10;10(12):e041981. doi: 10.1136/bmjopen-2020-041981.
BACKGROUND
The oncological safety of diagnostic hysteroscopy in patients with stage Ⅰ endometrial cancer remains uncertain and conflicting. The aim of the proposed systematic review and meta-analysis is to summarise the available evidence examining the association between diagnostic hysteroscopy and the prognosis of stage Ⅰ endometrial cancer and to statistically synthesise the results of relevant studies.
METHODS AND ANALYSIS
Systematic searches of PubMed/MEDLINE, Embase, Cochrane Library and Web of Science will be undertaken using prespecified search strategies. Two authors will independently conduct eligible studies selection process, perform data extraction and appraise the quality of included studies. Original case-control studies, cohort studies and randomised controlled trails published in English will be considered for inclusion. The outcomes of interest will be 5-year recurrence-free survival, disease-specific survival and overall survival. Meta-analyses will be performed to calculate pooled estimates.
ETHICS AND DISSEMINATION
Our study will be based on published data, and thus there is no requirement for ethics approval. The results will be shared through publication in a peer-reviewed journal and presentations at academic conferences.
PROSPERO REGISTRATION NUMBER
CRD42020193696.
背景
Ⅰ期子宫内膜癌患者行诊断性宫腔镜检查的肿瘤安全性仍不确定且存在争议。本系统评价和荟萃分析的目的是总结现有证据，以检查诊断性宫腔镜检查与Ⅰ期子宫内膜癌预后之间的关系，并对相关研究的结果进行统计学综合。
方法和分析
将使用预设的检索策略对 PubMed/MEDLINE、Embase、Cochrane 图书馆和 Web of Science 进行系统检索。两位作者将独立进行合格研究的选择过程、数据提取和纳入研究的质量评估。将考虑纳入原始病例对照研究、队列研究和随机对照试验，这些研究均以英文发表。感兴趣的结局将是 5 年无复发生存率、疾病特异性生存率和总生存率。将进行荟萃分析以计算汇总估计值。
伦理和传播
我们的研究将基于已发表的数据，因此不需要伦理批准。研究结果将通过发表在同行评议的期刊上和在学术会议上的报告进行分享。
PROSPERO 注册号：CRD42020193696。
Zotero 插件